Drug General Information
Drug ID	D03CPM
Former ID	DIB001555
Drug Name	SLV-334
Indication	Brain injury [ICD10:S09.90]		Phase 2	[531869]
Company	Solvay SA
Structure		Download 2D MOL 3D MOL
Target and Pathway
Target(s)	Neutral endopeptidase	Target Info	Modulator
	Endothelin converting enzyme	Target Info	Modulator
KEGG Pathway	Renin-angiotensin system
	Hematopoietic cell lineage
	Protein digestion and absorption
	Alzheimer's disease
NetPath Pathway	EGFR1 Signaling Pathway
	TGF_beta_Receptor Signaling Pathway
Reactome	Metabolism of Angiotensinogen to Angiotensins
WikiPathways	Metabolism of Angiotensinogen to Angiotensins
	Primary Focal Segmental Glomerulosclerosis FSGS
	Alzheimers Disease
References
Ref 531869	The dual endothelin converting enzyme/neutral endopeptidase inhibitor SLV-306 (daglutril), inhibits systemic conversion of big endothelin-1 in humans. Life Sci. 2012 Oct 15;91(13-14):743-8.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.